Farmacovigilanza SIF > Sezioni > Interazioni tra farmaci > Lansoprazolo (aggiornato al 5 novembre 2021)

Lansoprazolo (aggiornato al 5 novembre 2021)

A cura di Alessandra Russo. Specialista in Tossicologia Medica. Messina

 

Principio attivo

Effetto

Acalabrutinib (1)

Possibile riduzione dell’esposizione ad acalabrutinib.

Acenocumarolo (2)

Possibile aumento dei valori serici di INR (International Normalized Ratio) e possibile potenziamento degli effetti anticoagulanti.

Capecitabina (3,4)

Possibile riduzione della biodisponibilità della capecitabina.

Clopidogrel (5-8)

Possibile riduzione dell’attività antiaggregante piastrinica.

Erlotinib (9)

Possibile riduzione dell’esposizione ad erlotinib.

Levotiroxina (10,11)

Possibile riduzione dell’efficacia della levotiroxina.

Micofenolato mofetil (12,13)

Possibile riduzione dell’esposizione ad acido micofenolico, il metabolita attivo del micofenolato mofetil.

Pazopanib (14)

Possibile riduzione della biodisponibilità del pazopanib.

Sunitinib (15)

Possibile riduzione della biodisponibilità del sunitinib.

Tacrolimus (16)

Possibile aumento delle concentrazioni del tacrolimus.

Voriconazolo (17,18)

Possibile aumento delle concentrazioni plasmatiche del lansoprazolo.

Warfarin (2)

Possibile aumento dei valori serici di INR (International Normalized Ratio) e possibile potenziamento degli effetti anticoagulanti.

 

Bibliografia

  1. Product Information: CALQUENCE(R) oral capsules, acalabrutinib oral capsules. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, Oct, 2017.
  2. Product Information: Prevacid(R), lansoprazole. TAP Pharmaceuticals Inc., Lake Forest, IL, 11/2003.
  3. Chu MP, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol 2017; 3: 767-773.
  4. Sun J, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer 2016; 15: 257-263.
  5. Furuta T, et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43: 333-342.
  6. Ho PM, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
  7. Juurlink DN, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
  8. Pezalla E. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52: 1038-1039.
  9. Ohgami M, et al. Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer. Ther Drug Monit 2018; 40: 699-704.
  10. Irving S. Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf) 2015; 82: 136-141.
  11. Sachmechi I, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007; 13: 345-349.
  12. Kofler S, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients – a prospective case-controlled study. Am J Transplant 2009; 9: 1650-1656.
  13. Schaier M, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010; 49: 2061-2067.
  14. McAlister RK, et al. Effect of concomitant ph-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist 2018; 23: 686-692.
  15. Ha VH, et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 2015; 21: 194-200.
  16. Isoda K, et al. The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. Intern Med 2014; 53: 1413-1418.
  17. Lopez JL. Voriconazole-induced hepatitis via simvastatin-and lansoprazole-mediated drug interactions: a case report and review of the literature. Drug Metab Dispos 2016; 44: 124-126.
  18. Tsubokura M, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol 2011; 51: 1488-1490.

 

Link

Ultimo aggiornamento: 17 novembre 2021